… In conclusion, treatment with atezolizumab plus bevacizumab was associated with … in patients
with advanced unresectable hepatocellular carcinoma not previously treated with systemic …

… IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly … with
sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a …

… Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for
unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy …

… suggest that combining atezolizumab with bevacizumab can … in patients with unresectable
hepatocellular carcinoma. To … done to compare atezolizumab and bevacizumab combination …

… of atezolizumab plus bevacizumab than with atezolizumab alone in … We certainly agree
that the atezolizumab plus bevacizumab … advance in unresectable hepatocellular carcinoma. …

… combination of atezolizumab and bevacizumab demonstrated … unresectable HCC treated
with atezolizumab/bevacizumab … effectiveness of atezolizumab plus bevacizumab compared to …

… of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, …
unresectable HCC and no prior systemic treatment, including atezolizumab plus bevacizumab…

… with atezolizumab plus bevacizumab may prolong overall survival among patients with
unresectable hepatocellular carcinoma. … of atezolizumab plus bevacizumab to treat unresectable …

… atezolizumab plus bevacizumab. After IPTW adjustment, atezolizumab plus bevacizumab did
… OS was prolonged by atezolizumab plus bevacizumab over lenvatinib in viral patients (HR: …

… Understanding patients' experience of cancer treatment is important. We aimed to … atezolizumab
plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma …